Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• المؤلفون الرئيسيون: Ju Li (مؤلف), Zhongyuan Zhang (مؤلف), Xinhua Wu (مؤلف), Jie Zhou (مؤلف), Deqian Meng (مؤلف), Ping Zhu (مؤلف)
• التنسيق: كتاب
• منشور في: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...